LINC00261 can also be over-expressed in pancreatic cancer tissues by binding miR-222-3p to activate the HIPK2/ERK/c-myc pathway 43, which unmasked a new epigenetic and post-transcriptional regulatory mechanism that contributes to targeted therapy for pancreatic cancer. Here, LINC00261 is linked to pancreatic neoplasm.